-
1.发明授权Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis 有权使用因子VIIa或组织因子拮抗剂调节基因表达和细胞迁移或趋化性公开(公告)号：US07829529B2
公开(公告)日：2010-11-09
申请号：US12178126
申请日：2008-07-23
IPC分类号： C07K14/00
CPC分类号： C12N9/6437 , A61K38/00 , C12Y304/21021
摘要： The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.
摘要翻译： 本发明涉及FVII和/或FVIIa和/或另一种TF激动剂和/或FVIIa和/或另一种TF拮抗剂在治疗性治疗可能与细胞迁移相关的病理状况或通过细胞迁移的特异性调节或 趋化性。
-
公开(公告)号：US5817788A
公开(公告)日：1998-10-06
申请号：US327690
申请日：1994-10-24
申请人： Kathleen L. Berkner , Lars Christian Petersen , Charles E. Hart , Ulla Hedner , Claus Bregengaard
发明人： Kathleen L. Berkner , Lars Christian Petersen , Charles E. Hart , Ulla Hedner , Claus Bregengaard
CPC分类号： A61K38/166 , A61K38/49 , C12N9/6437 , C12Y304/21021
摘要： The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
-
公开(公告)号：US5859010A
公开(公告)日：1999-01-12
申请号：US880699
申请日：1997-06-23
IPC分类号： A61K31/16 , A61K31/415 , A61K31/4192 , A61K31/4439 , A61K31/4745 , A61K31/498 , A61K33/30 , C07D231/14 , C07D241/52 , A61K31/495 , C07C251/00 , C07C251/34 , C07D241/36
CPC分类号： C07D241/52 , A61K31/16 , A61K31/415 , A61K31/4192 , A61K31/4439 , A61K31/4745 , A61K31/498 , A61K33/30 , C07D231/14
摘要： The invention relates to novel compounds that potentiate zinc ion inhibition of the activity of factor VIIa or tissue factor--factor VIIa complex having the formula Ia and Ib and pharmaceutical salts thereof as well as pharmaceutical compositions comprising said novel compounds. The invention is further related to the use of said compositions for inhibiting clotting activity, tissue factor activity and factor VIIa activity.
摘要翻译： 本发明涉及增强锌离子抑制因子VIIa或具有式Ia和Ib的组织因子因子VIIa复合物及其药用盐的活性的锌离子抑制作用以及包含所述新化合物的药物组合物。 本发明进一步涉及所述组合物用于抑制凝血活性，组织因子活性和因子VIIa活性的用途。
-
公开(公告)号：US5833982A
公开(公告)日：1998-11-10
申请号：US660289
申请日：1996-06-07
申请人： Kathleen L. Berkner , Lars Christian Petersen , Charles E. Hart , Ulla Hedner , Claus Bregengaard
发明人： Kathleen L. Berkner , Lars Christian Petersen , Charles E. Hart , Ulla Hedner , Claus Bregengaard
IPC分类号： A61K38/55 , A61K38/00 , A61K38/16 , A61K38/36 , A61K38/43 , A61K38/48 , A61K38/49 , C07K14/745 , C12N9/64 , A61K35/14 , C12N9/48
CPC分类号： C12N9/6437 , A61K38/166 , A61K38/4846 , A61K38/49 , C12Y304/21021 , Y10S514/802
摘要： The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.
摘要翻译： 因子VII的催化活性位点被修饰以产生有效中断凝血级联的化合物。 修饰使得因子VIIa基本上不能激活血浆因子X或IX。 修饰因子VII的药物组合物用于治疗各种凝血相关疾病，包括血小板沉积，血管血栓形成，缺血再灌注，冠状动脉急性闭合，继发于球囊血管成形术的血管再狭窄，内膜切除术，还原性粥样斑块切除术，支架置入 ，激光治疗或旋转消融。
-
公开(公告)号：US06168789A
公开(公告)日：2001-01-02
申请号：US09189607
申请日：1998-11-10
申请人： Kathleen L. Berkner , Lars Christian Petersen , Charles E. Hart , Ulla Hedner , Claus Bregengaard
发明人： Kathleen L. Berkner , Lars Christian Petersen , Charles E. Hart , Ulla Hedner , Claus Bregengaard
IPC分类号： A61K3848
CPC分类号： C12N9/6437 , A61K38/166 , A61K38/4846 , A61K38/49 , C12Y304/21021 , Y10S514/802 , A61K2300/00
摘要： The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.
摘要翻译： 因子VII的催化活性位点被修饰以产生有效中断凝血级联的化合物。 修饰使得因子VIIa基本上不能激活血浆因子X或IX。 修饰因子VII的药物组合物用于治疗各种凝血相关疾病，包括血小板沉积，血管血栓形成，缺血再灌注，冠状动脉急性闭合，继发于球囊血管成形术的血管再狭窄，内膜切除术，还原性粥样斑块切除术，支架置入 ，激光治疗或旋转消融。
-
6.发明授权Antibodies that are capable of specifically binding tissue factor pathway inhibitor 有权能够特异性结合组织因子途径抑制剂的抗体公开(公告)号：US09260518B2
公开(公告)日：2016-02-16
申请号：US13805900
申请日：2011-06-30
申请人： Ida Hilden , Jes Thorn Clausen , Lars Christian Petersen , Brit Binow Soerensen , Helle Heibroch Petersen
发明人： Ida Hilden , Jes Thorn Clausen , Lars Christian Petersen , Brit Binow Soerensen , Helle Heibroch Petersen
IPC分类号： C07K16/38 , C07K16/28 , A61K39/395
CPC分类号： C07K16/28 , A61K39/395 , C07K16/38 , C07K2317/34 , C07K2317/76
摘要： The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
摘要翻译： 本发明涉及能够特异性结合组织因子途径抑制剂（TFPI），中和游离TFPI并降低血液凝血时间的抗体。 此外，本发明涉及编码这种抗体的多核苷酸以及包含多核苷酸或表达本发明的抗体的细胞。 这样的抗体可用于治疗具有凝血病的受试者，单独和与第二药剂组合。
-
7.发明申请Use of Factor VIIa or a Tissue Factor Antagonist for Regulating Gene Expression and Cell Migration or Chemotaxis 有权使用因子VIIa或组织因子拮抗剂调节基因表达和细胞迁移或趋化性公开(公告)号：US20090036378A1
公开(公告)日：2009-02-05
申请号：US12178126
申请日：2008-07-23
CPC分类号： C12N9/6437 , A61K38/00 , C12Y304/21021
摘要： The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.
摘要翻译： 本发明涉及FVII和/或FVIIa和/或另一种TF激动剂和/或FVIIa和/或另一种TF拮抗剂在治疗性治疗可能与细胞迁移相关的病理状况或通过细胞迁移的特异性调节或 趋化性。
-
8.发明授权Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis 失效使用组织因子激动剂或组织因子拮抗剂治疗与凋亡有关的病症公开(公告)号：US06858587B2
公开(公告)日：2005-02-22
申请号：US10285970
申请日：2002-11-01
CPC分类号： A61K38/4846
摘要： The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.
摘要翻译： 本发明涉及FVII和/或FVIIa和/或另一种TF激动剂和/或FVIIa和/或另一种TF拮抗剂在需要增加或减少细胞凋亡的病理状况的治疗性治疗中的用途。
-
9.发明授权Methods for modifying cell motility using factor VIIa or inactivated factor VIIa 有权使用因子VIIa或灭活因子Ⅶa修饰细胞运动的方法公开(公告)号：US06461610B1
公开(公告)日：2002-10-08
申请号：US09372888
申请日：1999-08-12
申请人： Lars Kongsbak , Niels Bergenhem , Lars Christian Petersen , Ole Thastrup , Don Foster , Mirella Ezban , Agneta Siegbahn
发明人： Lars Kongsbak , Niels Bergenhem , Lars Christian Petersen , Ole Thastrup , Don Foster , Mirella Ezban , Agneta Siegbahn
IPC分类号： A61K3848
CPC分类号： G01N33/5041 , A61K38/4846 , G01N33/5008 , G01N33/5011 , G01N33/5035 , G01N33/5044 , G01N33/5064 , G01N33/86 , G01N2333/96447
摘要： The present invention provides methods for modifying the motility of tissue factor (TF)-expressing cells, which are carried out by contacting such cells with an effective amount of Factor VIIai Factor VIIa agonist.
摘要翻译： 本发明提供了通过使这些细胞与有效量的因子VIIai因子VIIa激动剂接触而进行的改变组织因子（TF）表达细胞运动性的方法。
-
公开(公告)号：US20130142804A1
公开(公告)日：2013-06-06
申请号：US13805900
申请日：2011-06-30
申请人： Ida Hilden , Jes Thorn Clausen , Lars Christian Petersen , Brit Binow Soerensen , Helle Heibroch Petersen
发明人： Ida Hilden , Jes Thorn Clausen , Lars Christian Petersen , Brit Binow Soerensen , Helle Heibroch Petersen
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , A61K39/395 , C07K16/38 , C07K2317/34 , C07K2317/76
摘要： The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.017 秒)
